Board Member at BioAge Labs

BioAge Labs, Inc., a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, today announced the appointment of Michael Davidson, MD to the company’s board of directors.

CCO & SVP, Head of Chemistry at Odyssey Therapeutics

Odyssey Therapeutics, Inc., a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the appointment of Julie Clauss, MBA, as chief operating officer and Christopher Butler, Ph.D., as senior vice president (SVP), head of Chemistry. Together, these individuals bring more than 40 years of leadership experience and scientific expertise within the biotechnology and pharmaceutical industries to Odyssey.

Board Members at TOLREMO Therapeutics

TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Jeff Jonker and Mike Sherman to its Board of Directors. Both bring extensive careers in the strategic, financial and corporate development aspects of building leading biotechnology companies. Together, they will contribute to TOLREMO’s further growth and operational execution as the company advances its lead candidate, TT125-802, designed to prevent transcriptional cancer drug ...

Board Members at Nimble Therapeutics

Nimble Therapeutics announced that Dan Flynn and Brian Cali have joined the company’s Board of Directors. Both bring deep entrepreneurial and drug development track records that will guide Nimble as it continues to pursue its internal pipeline.

SVP, CMC & Tech Ops, CBO, and CFO at Venatorx Pharmaceuticals

Venatorx Pharmaceuticals, a private, pre-commercial pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections, announced expansion of its leadership team with three key industry veterans: Jason Burdette joining as Senior Vice President, CMC and Technical Operations: Armand Girard as Chief Business Officer; and Tamra Adams, and Chief Financial Officer. These appointments come ...

SVP, Technical Operations at RAPT Therapeutics

RAPT Therapeutics, Inc., a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations.

President at NMDP BioTherapies

NMDP BioTherapies℠, formerly Be The Match BioTherapies, announced that Tom Hochuli will serve as president, leading the organization into its promising future phase. The appointment comes at a significant time for NMDP, which underwent a unifying, organization-wide brand change earlier this year driven by its expanding global presence, industry-leading research and innovations in cell therapies, such as those led by NMDP BioTherapies.

Chief Technical Officer at Immunome

Immunome, Inc., a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Roberts as Chief Technical Officer. Mr. Roberts has over three decades of experience in product development, global manufacturing, and commercialization of novel pharmaceutical products.

CEO at Pacira BioSciences

Pacira BioSciences, Inc., the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (the “Board”) has appointed Frank D. Lee as Chief Executive Officer and a member of the Board, effective January 2, 2024. 

Senior Advisors at Related Sciences

Related Sciences, a leading data science-driven drug discovery firm, today announced the appointment of 8 leading biopharma executives as senior advisors to support its growing portfolio of drug programs, data science capabilities, and R&D partnerships. “We are thrilled to have assembled such a luminary group of senior pharma and biotech executives to support our leadership team as we continue to grow ...

SVP, Clinical Development Operations

Satellos Bioscience Inc., a publicly traded biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the following updates: AAK1 is the drug target of the Company’s lead drug program in Duchenne muscular dystrophy (“Duchenne” or “DMD”); IND-enabling studies and GMP manufacturing are ongoing; SAT-3247 has been nominated as its lead ...

CGO at Holmusk

 Holmusk, a leading global behavioral health real-world evidence company, today announced that it has appointed Eze Abosi as Chief Growth Officer, leading the organization’s commercial team. Eze has nearly two decades of experience leading commercialization of data, analytics and consulting solutions supporting the life sciences and biopharma industries. He joins Holmusk after serving as the Vice President of New Products and Partnership ...

CEO at I2Pure

I2Pure announced the hiring of its new Chief Executive Officer, Jeffrey Jochims, effective November 1, 2023. Jeff succeeds I2Pure Founder Douglas Spitz, who is transitioning to the role of Executive Chair. Jochims also joins the I2Pure Board of Directors.

Independent Directors at Pacira BioSciences

Pacira BioSciences, Inc., the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the appointments of Marcelo Bigal, MD, PhD, Abraham Ceesay, Michael Yang, and Alethia Young, to its Board of Directors effective immediately. “We are pleased to welcome these four highly seasoned executives to our Board of Directors, whose experience will enhance our ...

CTO at Aura Biosciences

Aura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the appointment of Mark Plavsic, Ph.D., as Chief Technology Officer.

President at Ontada

Ontada®, a McKesson business dedicated to leveraging oncology real-world data and evidence, clinical education, and provider technology, announced the appointment of Christine Davis as its new president. In this role, Davis will focus on growing the business and fostering innovation, all to improve the lives of patients and win the fight against cancer. With more than 25 years of experience in the ...

SVP, Head of Commercial and Business Development at Tourmaline Bio

Tourmaline Bio, Inc., a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune diseases, today announced the appointment of Gerhard Hagn, PharmD, to the newly created role of SVP, Head of Commercial and Business Development. In this role, Mr. Hagn will oversee commercial and business development strategy and planning.

CCO at Validic

Validic, a market-leading digital health and personalized care company, welcomed Jeff Cutler as chief commercial officer. In this role, Cutler will oversee Validic’s strategic approach to generating revenue across its portfolio of SaaS software solutions and services, owning its revenue model, go-to-market approach, and client experience leading sales, marketing, business development and client success.

CFO & CLO and Corporate Secretary at Aeglea BioTherapeutics

Aeglea BioTherapeutics, Inc., a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease (“IBD”), today announced the appointment of Scott Burrows, as Chief Financial Officer and Heidy Abreu King-Jones as Chief Legal Officer and Corporate Secretary.

Independent Chairman at Confo Therapeutics

Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced the appointment of Dieter Weinand as Independent Chairman of its Board of Directors. Mr. Weinand brings with him a wealth of experience with more than 35 years in the pharmaceutical industry and over 25 years as the leader of geographic and strategic business units ...

Chairman of Board at Apogee Therapeutics

Apogee Therapeutics, Inc., a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease and other inflammatory and immunology (I&I) indications, today announced the appointment of Mark C. McKenna as Chairman of its board of directors. Mr. McKenna’s knowledge and successful track record in the I&I space as well as his significant development, ...

CEO at Wellinks

Wellinks, the leading digital healthcare company offering virtual cardiopulmonary disease management for health plans and value-based care providers, today announced Stacie Bratcher as its new Chief Executive Officer.

Board Members at Apogee Therapeutics

Apogee Therapeutics, a biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease and related inflammatory and immunology indications, today announced the appointments of Jennifer Fox and William “BJ” Jones, seasoned executives in the biotechnology industry, to its board of directors. Ms. Fox will also serve as chair of the company’s audit committee.

CEO at 1859

1859, an AI-based small molecule drug discovery company advancing next generation medicines, is pleased to announce the appointment of Sanket Agrawal as its Chief Executive Officer (CEO), effective April 2023. As an experienced biopharma business leader, Agrawal joins 1859 to drive its next stage of growth and deliver on the company’s potential to rapidly discover superior molecules. The company has ...

SVP of Regulatory Affairs & Clinical Quality Assurance at Kronos Bio

Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Marc Besman Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance. Dr. Besman will be responsible for developing, implementing, and advancing global regulatory strategies for Kronos Bio’s portfolio. He will also ensure that the Company upholds the highest ...

CBO at Affini-T Therapeutics

Affini-T Therapeutics, Inc., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced the appointment of Thaminda Ramanayake as Chief Business Officer. Mr. Ramanayake is a business development and transactions specialist who has spent over a decade working to bring value to patients globally and has a strong track record in company creation, in/out-licensing, ...

CCO at AlloVir

AlloVir, a late-clinical stage allogeneic T cell immunotherapy company, today announced the appointment of Cintia Piccina, PharmD, MBA, as the company’s Chief Commercial Officer, effective June 12, 2023. Ms. Piccina will drive the global commercialization strategy for AlloVir, with a focus on its lead product, posoleucel, and be responsible for building a commercial team in anticipation of a 2025 launch.

CFO at Impel Pharmaceuticals

Impel Pharmaceuticals, a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Michael W. Kalb, CPA, as Chief Financial Officer, effective May 10, 2023.

CFO at Cognition Therapeutics

Cognition Therapeutics, Inc., today announced the appointment of John Doyle to the role of Chief Financial Officer. Mr. Doyle has substantial experience leading and managing financial operations at development- and commercial-stage public life sciences companies through financings, mergers, acquisitions and licensing agreements.

Board Member at Keros Therapeutics

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it appointed Alpna Seth, Ph.D., to its Board of Directors, effective May 1, 2023.

Board Member at Impel Pharmaceuticals

Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Darren Cline to the Board of Directors. 

Non-Executive Chairman at Venatorx Pharmaceuticals

“We are pleased to welcome Tom Heyman to our Board of Directors, “ said Christopher J. Burns, President and Chief Executive Officer. “As a highly respected and seasoned executive and board member, Tom brings a diverse breadth of industry experience across multiple disciplines that will benefit Venatorx as we continue to progress our pipeline of novel anti-infective therapies.

CMO at Shoreline Biosciences

Dr. Avanzi is an experienced physician-scientist and hematologist/oncologist with over fifteen years of clinical experience, including over ten years of experience advancing cellular therapies through early and late-stage of development.  In his new role, Dr. Avanzi will be responsible for leading and expanding Shoreline’s clinical portfolio and will serve as a key member of its Executive team.

CBO & CHRO at Elektrofi

Elektrofi strengthens leadership team with appointments of Greg DeFilippis as Chief Business Officer and Paulette Gangemi as Chief Human Resources Officer

CFO at Apogee Therapeutics

“Jane is a highly accomplished leader and multiple time CFO with significant expertise in corporate strategy and finance in the healthcare sector, and we are excited to welcome her to our leadership team,” said Michael Henderson, M.D., CEO of Apogee Therapeutics. “Her unique combination of experience as a seasoned biopharmaceutical executive and investment banker will help propel Apogee forward in its ...

CEO at Curve Health

Curve Health names Healthcare Veteran Matthew A. Michela as CEO to expand reach of senior care platform.